Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioRRA: Biomarkers of Remission in Rheumatoid Arthritis
NCT02219347Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Aug 2014
- Primary completion
- Aug 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of methotrexate, 5-aminosalicylic acid + sulphasalazine and hydroxychloroquine in rheumatoid arthritis (RA), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoint: Time-to-flare of arthritis activity at 6 months. Started Aug 2014; status: completed.
02
Drugs
methotrexate5-aminosalicylic acid + sulphasalazinehydroxychloroquine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02219347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02219347.